{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:37:56Z","timestamp":1792820276514,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"DOI":"10.1007\/s11657-026-01785-8","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:55:01Z","timestamp":1792774501000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Skeletal effects of GLP-1 receptor agonist therapy in adults with overweight or obesity: a systematic review"],"prefix":"10.1007","volume":"21","author":[{"given":"Cheng-Hao","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Tzu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Shuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9938-8827","authenticated-orcid":false,"given":"Chia-Ta","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"1785_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/obr.12244","volume":"16","author":"V Mpalaris","year":"2015","unstructured":"Mpalaris V, Anagnostis P, Goulis DG, Iakovou I (2015) Complex association between body weight and fracture risk in postmenopausal women. Obes Rev 16:225\u2013233. https:\/\/doi.org\/10.1111\/obr.12244","journal-title":"Obes Rev"},{"key":"1785_CR2","doi-asserted-by":"publisher","first-page":"8303","DOI":"10.3390\/ijms23158303","volume":"23","author":"A Pi\u00f1ar-Gutierrez","year":"2022","unstructured":"Pi\u00f1ar-Gutierrez A, Garc\u00eda-Fontana C, Garc\u00eda-Fontana B, Mu\u00f1oz-Torres M (2022) Obesity and bone health: a complex relationship. Int J Mol Sci 23:8303 https:\/\/doi.org\/10.3390\/ijms23158303","journal-title":"Int J Mol Sci"},{"key":"1785_CR3","doi-asserted-by":"publisher","unstructured":"Noubiap JJ, Nansseu JR, Nyaga UF et al (2025) Worldwide trends in metabolic syndrome from 2000 to 2023: a systematic review and modelling analysis. Nat Commun. Advance online publication. https:\/\/doi.org\/10.1038\/s41467-025-67268-5","DOI":"10.1038\/s41467-025-67268-5"},{"key":"1785_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2026.156492","volume":"177","author":"G Leanza","year":"2026","unstructured":"Leanza G, Faraj M, Cannata F et al (2026) Bone inflammation in postmenopausal women with type 2 diabetes or obesity in relation to Wnt signaling and bone strength. Metabolism 177: 156492. https:\/\/doi.org\/10.1016\/j.metabol.2026.156492","journal-title":"Metabolism"},{"key":"1785_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.981487","volume":"13","author":"D Ali","year":"2022","unstructured":"Ali D, Tencerova M, Figeac F, Kassem M, Jafari A (2022) The pathophysiology of osteoporosis in obesity and type 2 diabetes in aging women and men: the mechanisms and roles of increased bone marrow adiposity. Front Endocrinol 13:981487. https:\/\/doi.org\/10.3389\/fendo.2022.981487","journal-title":"Front Endocrinol"},{"key":"1785_CR6","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S2213-8587(24)00163-3","volume":"12","author":"J Paccou","year":"2024","unstructured":"Paccou J, Compston JE (2024) Bone health in adults with obesity before and after interventions to promote weight loss. Lancet Diab Endocrinol 12:748\u2013760. https:\/\/doi.org\/10.1016\/S2213-8587(24)00163-3","journal-title":"Lancet Diab Endocrinol"},{"key":"1785_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3389\/fphys.2016.00439","volume":"7","author":"B Roy","year":"2016","unstructured":"Roy B, Curtis ME, Fears LS, Nahashon SN, Fentress HM (2016) Molecular mechanisms of obesity-induced osteoporosis and muscle atrophy. Front Physiol 7:439. https:\/\/doi.org\/10.3389\/fphys.2016.00439","journal-title":"Front Physiol"},{"key":"1785_CR8","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.jocd.2013.08.010","volume":"16","author":"BA Gower","year":"2013","unstructured":"Gower BA, Casazza K (2013) Divergent effects of obesity on bone health. J Clin Densitom 16:450\u2013454. https:\/\/doi.org\/10.1016\/j.jocd.2013.08.010","journal-title":"J Clin Densitom"},{"key":"1785_CR9","doi-asserted-by":"publisher","unstructured":"Bagherifard A, Hemmatyar A, Khosravi K et al (2025) The impact of obesity on bone health: molecular pathways, metabolic interactions, and associated pathologies. Int J Obes. Advance online publication. https:\/\/doi.org\/10.1038\/s41366-025-01907-1","DOI":"10.1038\/s41366-025-01907-1"},{"key":"1785_CR10","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1001\/jama.2024.10816","volume":"332","author":"KA Gudzune","year":"2024","unstructured":"Gudzune KA, Kushner RF (2024) Medications for obesity: a review. JAMA 332:571\u2013584. https:\/\/doi.org\/10.1001\/jama.2024.10816","journal-title":"JAMA"},{"key":"1785_CR11","doi-asserted-by":"publisher","first-page":"8214","DOI":"10.3390\/ijms25158214","volume":"25","author":"Z Szekeres","year":"2024","unstructured":"Szekeres Z, Nagy A, Jahner K, Szabados E (2024) Impact of selected glucagon-like peptide-1 receptor agonists on serum lipids, adipose tissue, and muscle metabolism: a narrative review. Int J Mol Sci 25:8214. https:\/\/doi.org\/10.3390\/ijms25158214","journal-title":"Int J Mol Sci"},{"key":"1785_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/17425255.2018.1420160","volume":"14","author":"M Molina Vega","year":"2018","unstructured":"Molina Vega M, Mu\u00f1oz-Garach A, Tinahones FJ (2018) Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol 14:207\u2013217. https:\/\/doi.org\/10.1080\/17425255.2018.1420160","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1785_CR13","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ijcard.2016.06.028","volume":"219","author":"N Su","year":"2016","unstructured":"Su N, Li Y, Xu T et al (2016) Exenatide in obese or overweight patients without diabetes: a systematic review and meta-analyses of randomized controlled trials. Int J Cardiol 219:293\u2013300. https:\/\/doi.org\/10.1016\/j.ijcard.2016.06.028","journal-title":"Int J Cardiol"},{"key":"1785_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102782","volume":"75","author":"N Alfaris","year":"2024","unstructured":"Alfaris N, Waldrop S, Johnson V, Boaventura B, Kendrick K, Stanford FC (2024) GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review. EClinicalMedicine 75:102782. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102782","journal-title":"EClinicalMedicine"},{"key":"1785_CR15","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1007\/s00198-025-07664-1","volume":"36","author":"L Karam","year":"2025","unstructured":"Karam L, Mabilleau G, Paccou J (2025) Effects of glucagon-like peptide-1 receptor agonists on bone health in people living with obesity. Osteoporos Int 36:2115\u20132126. https:\/\/doi.org\/10.1007\/s00198-025-07664-1","journal-title":"Osteoporos Int"},{"key":"1785_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s12020-025-04253-4","volume":"89","author":"A Al Refaie","year":"2025","unstructured":"Al Refaie A, Baldassini L, Mondillo C et al (2025) Glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the treatment of type 2 diabetes mellitus: friends or foes to bone health? A narrative review of clinical studies. Endocrine 89:30\u201338. https:\/\/doi.org\/10.1007\/s12020-025-04253-4","journal-title":"Endocrine"},{"key":"1785_CR17","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00592-025-02468-5","volume":"62","author":"Y Tan","year":"2025","unstructured":"Tan Y, Liu S, Tang Q (2025) Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis. Acta Diabetol 62:589\u2013606. https:\/\/doi.org\/10.1007\/s00592-025-02468-5","journal-title":"Acta Diabetol"},{"key":"1785_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/1785321","volume":"2024","author":"X Li","year":"2024","unstructured":"Li X, Li Y, Lei C (2024) Effects of glucagon-like peptide-1 receptor agonists on bone metabolism in type 2 diabetes mellitus: a systematic review and meta-analysis. Int J Endocrinol 2024: 1785321. https:\/\/doi.org\/10.1155\/2024\/1785321","journal-title":"Int J Endocrinol"},{"key":"1785_CR19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s00223-023-01150-8","volume":"114","author":"J Herrou","year":"2024","unstructured":"Herrou J, Mabilleau G, Lecerf JM, Thomas T, Biver E, Paccou J (2024) Narrative review of effects of glucagon-like peptide-1 receptor agonists on bone health in people living with obesity. Calcif Tissue Int 114:86\u201397. https:\/\/doi.org\/10.1007\/s00223-023-01150-8","journal-title":"Calcif Tissue Int"},{"key":"1785_CR20","doi-asserted-by":"publisher","first-page":"l6890","DOI":"10.1136\/bmj.l6890","volume":"368","author":"M Campbell","year":"2020","unstructured":"Campbell M, McKenzie JE, Sowden A et al (2020) Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ 368:l6890. https:\/\/doi.org\/10.1136\/bmj.l6890","journal-title":"BMJ"},{"key":"1785_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102624","volume":"72","author":"MS Hansen","year":"2024","unstructured":"Hansen MS, W\u00f6lfel EM, Jeromdesella S et al (2024) Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial. EClinicalMedicine 72:102624. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102624","journal-title":"EClinicalMedicine"},{"key":"1785_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.115197","volume":"132","author":"K Hygum","year":"2020","unstructured":"Hygum K, Harsl\u00f8f T, J\u00f8rgensen NR, Rungby J, Pedersen SB, Langdahl BL (2020) Bone resorption is unchanged by liraglutide in type 2 diabetes patients: a randomised controlled trial. Bone 132:115197. https:\/\/doi.org\/10.1016\/j.bone.2019.115197","journal-title":"Bone"},{"key":"1785_CR23","doi-asserted-by":"publisher","first-page":"e2416775","DOI":"10.1001\/jamanetworkopen.2024.16775","volume":"7","author":"SBK Jensen","year":"2024","unstructured":"Jensen SBK, S\u00f8rensen V, Sandsdal RM et al (2024) Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial. JAMA Netw Open 7:e2416775. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.16775","journal-title":"JAMA Netw Open"},{"key":"1785_CR24","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/3361309","volume":"2021","author":"TT Cai","year":"2021","unstructured":"Cai TT, Li HQ, Jiang LL et al (2021) Effects of GLP-1 receptor agonists on bone mineral density in patients with type 2 diabetes mellitus: a 52-week clinical study. Biomed Res Int 2021: 3361309. https:\/\/doi.org\/10.1155\/2021\/3361309","journal-title":"Biomed Res Int"},{"key":"1785_CR25","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3389\/fpsyt.2018.00781","volume":"9","author":"R Eriksson","year":"2019","unstructured":"Eriksson R, Broberg BV, Ish\u00f8y PL et al (2019) Bone status in obese, non-diabetic, antipsychotic-treated patients, and effects of the glucagon-like peptide-1 receptor agonist exenatide on bone turnover markers and bone mineral density. Front Psychiatry 9:781. https:\/\/doi.org\/10.3389\/fpsyt.2018.00781","journal-title":"Front Psychiatry"},{"key":"1785_CR26","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/j.1463-1326.2010.01355.x","volume":"13","author":"MC Bunck","year":"2010","unstructured":"Bunck MC, Eliasson B, Corn\u00e9r A et al (2010) Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. Diab Obes Metab 13:374\u2013377. https:\/\/doi.org\/10.1111\/j.1463-1326.2010.01355.x","journal-title":"Diab Obes Metab"},{"key":"1785_CR27","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00592-015-0792-2","volume":"52","author":"R Li","year":"2015","unstructured":"Li R, Xu W, Luo S et al (2015) Effect of exenatide, insulin and pioglitazone on bone metabolism in patients with newly diagnosed type 2 diabetes. Acta Diabetol 52:1083\u20131091. https:\/\/doi.org\/10.1007\/s00592-015-0792-2","journal-title":"Acta Diabetol"},{"key":"1785_CR28","doi-asserted-by":"publisher","first-page":"e35394","DOI":"10.1097\/MD.0000000000035394","volume":"102","author":"OZ Akyay","year":"2023","unstructured":"Akyay OZ, Canturk Z, Selek A et al (2023) The effects of exenatide and insulin glargine treatments on bone turnover markers and bone mineral density in postmenopausal patients with type 2 diabetes mellitus. Medicine 102:e35394. https:\/\/doi.org\/10.1097\/MD.0000000000035394","journal-title":"Medicine"},{"key":"1785_CR29","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.ajcnut.2023.04.017","volume":"118","author":"Y Liu","year":"2023","unstructured":"Liu Y, Ruan B, Jiang H et al (2023) The weight-loss effect of GLP-1RAs glucagon-like peptide-1 receptor agonists in non-diabetic individuals with overweight or obesity: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials. Am J Clin Nutr 118:614\u2013626. https:\/\/doi.org\/10.1016\/j.ajcnut.2023.04.017","journal-title":"Am J Clin Nutr"},{"key":"1785_CR30","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2337\/dc24-1678","volume":"48","author":"HJ Wong","year":"2025","unstructured":"Wong HJ, Sim B, Teo YH et al (2025) Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials. Diab Care 48:292\u2013300. https:\/\/doi.org\/10.2337\/dc24-1678","journal-title":"Diab Care"},{"key":"1785_CR31","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.stemcr.2016.02.002","volume":"6","author":"J Meng","year":"2016","unstructured":"Meng J, Ma X, Wang N et al (2016) Activation of GLP-1 receptor promotes bone marrow stromal cell osteogenic differentiation through \u03b2-catenin. Stem Cell Rep 6:579\u2013591. https:\/\/doi.org\/10.1016\/j.stemcr.2016.02.002","journal-title":"Stem Cell Rep"},{"key":"1785_CR32","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.bone.2015.08.006","volume":"81","author":"M Pereira","year":"2015","unstructured":"Pereira M, Jeyabalan J, J\u00f8rgensen CS et al (2015) Chronic administration of glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice. Bone 81:459\u2013467. https:\/\/doi.org\/10.1016\/j.bone.2015.08.006","journal-title":"Bone"},{"key":"1785_CR33","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/jbmr.2407","volume":"30","author":"AL Evans","year":"2015","unstructured":"Evans AL, Paggiosi MA, Eastell R, Walsh JS (2015) Bone density, microstructure and strength in obese and normal weight men and women in younger and older adulthood. J Bone Min Res 30:920\u2013928. https:\/\/doi.org\/10.1002\/jbmr.2407","journal-title":"J Bone Min Res"},{"key":"1785_CR34","doi-asserted-by":"publisher","first-page":"7988","DOI":"10.3390\/ijms25147988","volume":"25","author":"MSS Saadi","year":"2024","unstructured":"Saadi MSS, Das R, Mullath Ullas A et al (2024) Impact of different anti-hyperglycaemic treatments on bone turnover markers and bone mineral density in type 2 diabetes mellitus patients: a systematic review and meta-analysis. Int J Mol Sci 25:7988. https:\/\/doi.org\/10.3390\/ijms25147988","journal-title":"Int J Mol Sci"},{"key":"1785_CR35","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/bcp.12777","volume":"81","author":"G Luo","year":"2016","unstructured":"Luo G, Liu H, Lu H (2016) Glucagon-like peptide-1 (GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients?. Br J Clin Pharm 81:78\u201388. https:\/\/doi.org\/10.1111\/bcp.12777","journal-title":"Br J Clin Pharm"},{"key":"1785_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-025-09022-y","volume":"26","author":"YJ Alalwani","year":"2025","unstructured":"Alalwani YJ, Alshahrani AS, Alsudays AI et al (2025) Differential effects of GLP-1 receptor agonists on diabetic osteopathy in type 2 diabetes: a patient-stratified network meta-analysis. BMC Musculoskelet Disord 26:742. https:\/\/doi.org\/10.1186\/s12891-025-09022-y","journal-title":"BMC Musculoskelet Disord"},{"key":"1785_CR37","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1111\/bph.16421","volume":"181","author":"Z Chen","year":"2024","unstructured":"Chen Z, Wang Y, Zhang G et al (2024) Role of LRP5\/6\/GSK-3\u03b2\/\u03b2-catenin in the differences in exenatide- and insulin-promoted T2D osteogenesis and osteomodulation. Br J Pharm 181:3556\u20133575. https:\/\/doi.org\/10.1111\/bph.16421","journal-title":"Br J Pharm"},{"key":"1785_CR38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fendo.2019.00051","volume":"10","author":"SA Mansur","year":"2019","unstructured":"Mansur SA, Mieczkowska A, Flatt PR, Chappard D, Irwin N, Mabilleau G (2019) The GLP-1 receptor agonist exenatide ameliorates bone composition and tissue material properties in high fat fed diabetic mice. Front Endocrinol 10:51. https:\/\/doi.org\/10.3389\/fendo.2019.00051","journal-title":"Front Endocrinol"},{"key":"1785_CR39","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1001\/jama.2025.6003","volume":"334","author":"SN Morin","year":"2025","unstructured":"Morin SN, Leslie WD, Schousboe JT (2025) Osteoporosis: a review. JAMA 334:894\u2013907. https:\/\/doi.org\/10.1001\/jama.2025.6003.","journal-title":"JAMA"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01785-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-026-01785-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01785-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:01:47Z","timestamp":1792818107000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-026-01785-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1785"],"URL":"https:\/\/doi.org\/10.1007\/s11657-026-01785-8","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study is a systematic review of previously published data.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Cheng-Hao Lai, Yu-Tzu Li, Ting-Shuan Wu, and Chia-Ta Wu declare that they have no conflict of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"148"}}